Elias Sayour, MD, PhD - Research

Research at a glance

Top areas of exploration

Glioblastoma , 12 publications
Immunotherapy , 11 publications
Brain Neoplasms , 10 publications
T-Lymphocytes , 7 publications

Research activity

56 publications

2,148 citations

Why is this important?

Focus

Active clinical trials

PBTC-060

Patients will receive a vaccine called SurVaxM on this study. While vaccines are usually thought of as ways to prevent diseases, vaccines can also be used to treat cancer. SurVaxM is designed to tell the body's immune system to look for tumor cells鈥�

Investigators: Elias Sayour, Jennifer F King
Status: Accepting Candidates
Ages: 1 Year - 21 Years
Sexes: All

My publications

56 publications

2024

Expanded specific T聽cells to hypomutated regions of the SARS-CoV-2 using mRNA electroporated antigen-presenting cells.

Molecular therapy. Methods & clinical development

鈥�

2024

RNA aggregates harness the danger response for potent cancer immunotherapy

Cell

鈥�

2024

Vaccines: a promising therapy for myelodysplastic syndrome.

Journal of hematology & oncology

鈥�

2023

Association of Suppressive Myeloid Cell Enrichment with Aggressive Oropharynx Squamous Cell Carcinoma.

Cancers

鈥�

2023

Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions

Acta Biomaterialia

网红黑料

Research at a glance

Top areas of exploration

Research activity

Focus

Active clinical trials

My publications

Filter publications

Expanded specific T聽cells to hypomutated regions of the SARS-CoV-2 using mRNA electroporated antigen-presenting cells.

RNA aggregates harness the danger response for potent cancer immunotherapy

Vaccines: a promising therapy for myelodysplastic syndrome.

Association of Suppressive Myeloid Cell Enrichment with Aggressive Oropharynx Squamous Cell Carcinoma.

Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions